Streetbeat News

Price Targets

CRMD

CorMedix has resubmitted its New Drug Application for DefenCath to the FDA, with potential approval in 2023. JMP Securities has increased the price target for CorMedix from $16 to $19, maintaining a Market Outperform rating. The company has a cash position of $59 million, sufficient to fund operations until 1H 2024.

Portfolio Pulse from Vandana Singh

May 19, 2023 | 6:09 pm

RELI

EF Hutton analyst Edward Reilly maintains a Buy rating on Reliance Global Group (NASDAQ:RELI) and raises the price target from $4 to $7.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 6:07 pm

AMAM

Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a price target of $25. The analyst believes the peak sales potential of Ambrx's pipeline of antibody-drug conjugates (ADCs) is underappreciated and that the company has sufficient capital to execute its development plans into 2025.

Portfolio Pulse from Vandana Singh

May 19, 2023 | 6:04 pm

BABA

Analysts re-rated Alibaba (NYSE:BABA) after the company shared its IPO plans for the Cloud division and posted upbeat Q4 results. However, the competition in Commerce & Cloud and the major reorganization are expected to weigh on the stock in the short term before driving value creation in the mid and long term.

Portfolio Pulse from Anusuya Lahiri

May 19, 2023 | 5:51 pm

SHOP

A whale has taken a bearish stance on Shopify (NYSE: SHOP) with 72% of detected unusual options trades being bearish. The price of SHOP is down 1.28% at $60.07. Analysts have mixed ratings on the stock, with price targets ranging from $45 to $80.

Portfolio Pulse from Benzinga Insights

May 19, 2023 | 5:46 pm

STXS

B. Riley has set a Buy rating and a $5.50 price target for Stereotaxis (STXS), a medical technology company.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 5:41 pm

DRUNF

TD Securities analyst Sam Damiani maintains a Buy rating on DREAM Unlimited (OTC:DRUNF) but lowers the price target from $43 to $35.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 5:39 pm

KELYA

Barrington Research analyst Kevin Steinke maintains an Outperform rating on Kelly Services (NASDAQ:KELYA) and raises the price target from $23 to $25.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 5:25 pm

TIGR

Daiwa Capital analyst Ling Tan downgraded UP Fintech Holding (NASDAQ:TIGR) from Buy to Hold and lowered the price target from $6 to $2.45.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 5:15 pm

LPCN

Zacks Small-Cap Research has set a $40 price valuation for Lipocine (LPCN), stating that they expect all of Lipocine's assets to be developed by partners, with the company receiving upfront payments, milestones, and royalties.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 5:03 pm